{"title":"Prospect of immunotherapy alone in patients with advanced NSCLC with high btmb: a review and a meta-analysis","authors":"Feiyu Zhao, Xiaochen Qiu, Qinna Yang, Shuyue Gao, Fan Yang, Niansong Qian","doi":"10.1007/s44178-023-00065-6","DOIUrl":"https://doi.org/10.1007/s44178-023-00065-6","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"22 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138948436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-20DOI: 10.1007/s44178-023-00066-5
Yichen Jin, Fan Yang, Kezhong Chen
{"title":"An overview of current development and barriers on liquid biopsy in patients with early-stage non-small-cell Lung cancer","authors":"Yichen Jin, Fan Yang, Kezhong Chen","doi":"10.1007/s44178-023-00066-5","DOIUrl":"https://doi.org/10.1007/s44178-023-00066-5","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"12 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138955403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1007/s44178-023-00064-7
A. H. Nwabo Kamdje, Richard Tagne Simo, Hetvet Paulain Fogang Dongmo, Amel Renaud Bidias, Palmer Masumbe Netongo
{"title":"Role of signaling pathways in the interaction between microbial, inflammation and cancer","authors":"A. H. Nwabo Kamdje, Richard Tagne Simo, Hetvet Paulain Fogang Dongmo, Amel Renaud Bidias, Palmer Masumbe Netongo","doi":"10.1007/s44178-023-00064-7","DOIUrl":"https://doi.org/10.1007/s44178-023-00064-7","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138615619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Purpose Peripheral T-cell lymphoma (PTCL) is notorious for its heterogeneity as well as poor prognosis. High mortality remains a challenge. Our study aims to assess whether the leukocyte-lymphocyte ratio (LLR) and neutrophil-lymphocyte ratio (NLR) can be applied as prognostic indexes for patients with PTCL and supplement the prognostic system of PTCL. Methods We reviewed the data of 108 newly diagnosed PTCL patients in the clinic. The χ 2 test was applied to contrast baseline characteristics between patients in different groups divided according to the cut-off value of LLR or NLR. The Kaplan-Meier method was adapted to develop the survival curve. The COX ratio risk regression model was used to identify the indexes related to patient survival. Results LLR ≥ 10.30, NLR ≥ 8.25, Eastern Cooperative Oncology Group (ECOG) score ≥ 2, International prognostic index (IPI) score > 2, Prognostic Index for T cell lymphoma (PIT) ≥ 2, B symptom, Ann Arbor stage III-IV and high level of Lactic dehydrogenase (LDH) were poor prognosis factors impacting patients’ overall survival (OS) by the univariate analysis. The multivariate analysis illustrated that only LLR ≥ 10.30 was significantly related to OS ( P all < 0.05). Conclusion Overall, our analysis revealed that LLR ≥ 10.30 was significantly associated with poorer OS and was a novel prognostic index for PTCL.
{"title":"Identification of leukocyte-lymphocyte ratio as a novel prognostic factor in Peripheral T-cell lymphoma","authors":"Shi-Qi Gao, Bo-Ya Lei, Yue Xu, Zi-Jian Zhang, Xing-Jian Niu, Wen-Hui Zhao, Qing-Yuan Zhang, Shu Zhao","doi":"10.1007/s44178-023-00062-9","DOIUrl":"https://doi.org/10.1007/s44178-023-00062-9","url":null,"abstract":"Abstract Purpose Peripheral T-cell lymphoma (PTCL) is notorious for its heterogeneity as well as poor prognosis. High mortality remains a challenge. Our study aims to assess whether the leukocyte-lymphocyte ratio (LLR) and neutrophil-lymphocyte ratio (NLR) can be applied as prognostic indexes for patients with PTCL and supplement the prognostic system of PTCL. Methods We reviewed the data of 108 newly diagnosed PTCL patients in the clinic. The χ 2 test was applied to contrast baseline characteristics between patients in different groups divided according to the cut-off value of LLR or NLR. The Kaplan-Meier method was adapted to develop the survival curve. The COX ratio risk regression model was used to identify the indexes related to patient survival. Results LLR ≥ 10.30, NLR ≥ 8.25, Eastern Cooperative Oncology Group (ECOG) score ≥ 2, International prognostic index (IPI) score > 2, Prognostic Index for T cell lymphoma (PIT) ≥ 2, B symptom, Ann Arbor stage III-IV and high level of Lactic dehydrogenase (LDH) were poor prognosis factors impacting patients’ overall survival (OS) by the univariate analysis. The multivariate analysis illustrated that only LLR ≥ 10.30 was significantly related to OS ( P all < 0.05). Conclusion Overall, our analysis revealed that LLR ≥ 10.30 was significantly associated with poorer OS and was a novel prognostic index for PTCL.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"121 7-8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136381488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Purpose We aimed to analyse the correlation between prostaglandin D2 synthase (PTGDS) and a diffuse large B-cell lymphoma (DLBCL) prognosis. Methods We retrospectively collected two hundred paraffin-embedded tissue specimens that were pathologically diagnosed as DLBCL in the Fujian Tumour Hospital between January 2014 and December 2018. An abundance of paraffin-embedded tumour tissues were obtained. Twenty patients with lymphocyte-rich, benign, tissue-reactive, hypertrophic tonsillitis were selected as controls. Wax blocks were selected for primary cases and the controls were screened by professional pathologists. The levels of prostaglandin D2 synthase (PTGDS) and the EMT-related molecules, E-cadherin and vimentin, were detected by immunohistochemistry in clinical samples. A chi-square test revealed the correlations between PTGDS expression and clinicopathological characteristics, including age, sex, primary site, clinical stage, immunotyping, and International Prognostic Index (IPI) score. The Kaplan–Meier survival analysis was performed, and the diagnostic value was evaluated by receiver operating characteristic (ROC) curve analysis. Results A total of 138 cases (69%) were found to be PTGDS positive (> 30% positive cells). PTGDS staining was negative (< 30% positive cells) in 62 cases (31%). We collected the corresponding clinicopathological information and found that PTGDS expression was not significantly related to the patients’ age, tumour stage, presence of extranodal invasion, or IPI score. According to the follow-up data, patients with low PTGDS expression had poor progression-free survival (PFS) and overall survival (OS), with 2-year PFS and OS rates of 41.7% and 50%, respectively. The 2-year PFS and OS rates of PTGDS-positive patients were 89.3% and 92.9%, respectively ( P < 0.0001), and the differences were significant. Conclusion We found that the expression level of PTGDS is significantly correlated with the prognosis of diffuse large B-cell lymphoma.
{"title":"Prognostic analysis of prostaglandin D2 synthase in diffuse large B-cell lymphoma","authors":"Jiesong Wang, Yun Xu, Wei Yu, Yanbin Zheng, Hongming He, Daoguang Chen, Siping Zou, Chang Wang, Ying Chen, Ningbin Chen, Hui Wu, Jianchao Wang, Jianyang Lin","doi":"10.1007/s44178-023-00060-x","DOIUrl":"https://doi.org/10.1007/s44178-023-00060-x","url":null,"abstract":"Abstract Purpose We aimed to analyse the correlation between prostaglandin D2 synthase (PTGDS) and a diffuse large B-cell lymphoma (DLBCL) prognosis. Methods We retrospectively collected two hundred paraffin-embedded tissue specimens that were pathologically diagnosed as DLBCL in the Fujian Tumour Hospital between January 2014 and December 2018. An abundance of paraffin-embedded tumour tissues were obtained. Twenty patients with lymphocyte-rich, benign, tissue-reactive, hypertrophic tonsillitis were selected as controls. Wax blocks were selected for primary cases and the controls were screened by professional pathologists. The levels of prostaglandin D2 synthase (PTGDS) and the EMT-related molecules, E-cadherin and vimentin, were detected by immunohistochemistry in clinical samples. A chi-square test revealed the correlations between PTGDS expression and clinicopathological characteristics, including age, sex, primary site, clinical stage, immunotyping, and International Prognostic Index (IPI) score. The Kaplan–Meier survival analysis was performed, and the diagnostic value was evaluated by receiver operating characteristic (ROC) curve analysis. Results A total of 138 cases (69%) were found to be PTGDS positive (> 30% positive cells). PTGDS staining was negative (< 30% positive cells) in 62 cases (31%). We collected the corresponding clinicopathological information and found that PTGDS expression was not significantly related to the patients’ age, tumour stage, presence of extranodal invasion, or IPI score. According to the follow-up data, patients with low PTGDS expression had poor progression-free survival (PFS) and overall survival (OS), with 2-year PFS and OS rates of 41.7% and 50%, respectively. The 2-year PFS and OS rates of PTGDS-positive patients were 89.3% and 92.9%, respectively ( P < 0.0001), and the differences were significant. Conclusion We found that the expression level of PTGDS is significantly correlated with the prognosis of diffuse large B-cell lymphoma.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"15 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136381385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-20DOI: 10.1007/s44178-023-00057-6
Xianqun Fan
Abstract Cancer immunotherapy represents a groundbreaking paradigm shift in the field of cancer treatment, harnessing the power of the immune system to combat cancer cells. As an innovative approach, it has shown immense promise and has revolutionized the way we perceive and treat cancer. This commentary aims to highlight the recent important advances in cancer immunotherapy, including immune checkpoint blockade therapy, chimeric antigen receptor T cell therapy, T cell receptor-gene engineered T cell therapy, and tumor vaccines.
{"title":"Recent highlights of cancer immunotherapy","authors":"Xianqun Fan","doi":"10.1007/s44178-023-00057-6","DOIUrl":"https://doi.org/10.1007/s44178-023-00057-6","url":null,"abstract":"Abstract Cancer immunotherapy represents a groundbreaking paradigm shift in the field of cancer treatment, harnessing the power of the immune system to combat cancer cells. As an innovative approach, it has shown immense promise and has revolutionized the way we perceive and treat cancer. This commentary aims to highlight the recent important advances in cancer immunotherapy, including immune checkpoint blockade therapy, chimeric antigen receptor T cell therapy, T cell receptor-gene engineered T cell therapy, and tumor vaccines.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"15 21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135616160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-20DOI: 10.1007/s44178-023-00061-w
Zhu Jiayu, Qingyuan Zhang
Abstract Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in adults with high heterogeneity. Recent studies have manifested that the occurrence and development of DLBCL is related to hepatitis B virus (HBV) infection. As a medium-to-high prevalence area of HBV infection in China, the importance and exact mechanism of HBV infection in the occurrence of DLBCL have attracted considerable attention. HBV-associated DLBCL has unique clinical characteristics, poor treatment effect and inferior prognosis. HBV reactivation caused by DLBCL treatment also needs for constant vigilance. In this review we summarize the current research progress in the epidemiology, pathogenesis, clinical characteristics, HBV reactivation and antiviral therapies of HBV-associated DLBCL, in order to provide reference for clinical diagnosis and treatment.
{"title":"Hepatitis B virus–associated diffuse large B cell lymphoma: epidemiology, biology, clinical features and HBV reactivation","authors":"Zhu Jiayu, Qingyuan Zhang","doi":"10.1007/s44178-023-00061-w","DOIUrl":"https://doi.org/10.1007/s44178-023-00061-w","url":null,"abstract":"Abstract Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in adults with high heterogeneity. Recent studies have manifested that the occurrence and development of DLBCL is related to hepatitis B virus (HBV) infection. As a medium-to-high prevalence area of HBV infection in China, the importance and exact mechanism of HBV infection in the occurrence of DLBCL have attracted considerable attention. HBV-associated DLBCL has unique clinical characteristics, poor treatment effect and inferior prognosis. HBV reactivation caused by DLBCL treatment also needs for constant vigilance. In this review we summarize the current research progress in the epidemiology, pathogenesis, clinical characteristics, HBV reactivation and antiviral therapies of HBV-associated DLBCL, in order to provide reference for clinical diagnosis and treatment.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135570252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-17DOI: 10.1007/s44178-023-00059-4
Lijie Xing, Hui Wang, Dan Liu, Qiang He, Zengjun Li
Abstract Objective Richter syndrome (RS) occurs in approximately 2–10% of chronic lymphocytic leukemia (CLL) patients, more often during the disease course than at diagnosis, with a diffuse large B-cell Lymphoma (DLBCL) histology in 95% of cases. Despite great advances in the treatment of CLL in recent years, RS also develops in patients treated with novel agents, as summarized in our case report and review. Methods We summarized 3 patients with RS treated with immunochemotherapy combined with BTK inhibitor (BTKi) or BCL2 inhibitor (BCL2i) and reviewed the literature. Results Three RS patients were summarized. Patient 1 was transformed into DLBCL during dose reductions in ibrutinib and achieved bone marrow (BM) minimal residual disease (MRD)-negative complete response (CR) after rituximab etoposide, dexamethasone, doxorubicin, cyclophosphamide, and vincristine (R-EDOCH) combined with BTKi treatment and sustained progression-free survival (PFS) for more than 2 years. Patient 2, who transformed at the time of diagnosis, progressed after being treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), followed by PD1 antibody combined with cytosine, arabinoside, cisplatin and dexamethasone (DHAP) treatment and PD1 antibody combined with ifosfamide, carboplatin, and etoposide (ICE) treatment. Patient 2 achieved CR after treatment with rituximab, gemcitabine, and oxaliplatin (R-GemOx) combined with BTKi. Patient 3, who transformed at the time of diagnosis with CARD11, TP53, and ATM mutations, progressed after being treated with R-EDOCH combined with BTKi and achieved MRD-negative CR after treatment with R-GemOx and venetoclax, which has continued for 3 months. We summarized new protocols utilizing targeted therapy, such as BTKi acalabrutinib, and checkpoint inhibition, and the potential role of precision medicine in future trials of RS treatment. The efficacy of these protocols as single agents or in combination with immunochemotherapy is currently being evaluated. Conclusion In our study, immunochemotherapy combined with BTKi or BCL2i achieved favorable efficacy in the treatment of RS. The treatments should be optimized by the combination of both chemotherapies and targeted therapy to develop a specific individual approach for each patient, according to previous treatment and biological characteristics.
{"title":"Immunochemotherapy combined with novel agents for Richter syndrome: report of 3 cases","authors":"Lijie Xing, Hui Wang, Dan Liu, Qiang He, Zengjun Li","doi":"10.1007/s44178-023-00059-4","DOIUrl":"https://doi.org/10.1007/s44178-023-00059-4","url":null,"abstract":"Abstract Objective Richter syndrome (RS) occurs in approximately 2–10% of chronic lymphocytic leukemia (CLL) patients, more often during the disease course than at diagnosis, with a diffuse large B-cell Lymphoma (DLBCL) histology in 95% of cases. Despite great advances in the treatment of CLL in recent years, RS also develops in patients treated with novel agents, as summarized in our case report and review. Methods We summarized 3 patients with RS treated with immunochemotherapy combined with BTK inhibitor (BTKi) or BCL2 inhibitor (BCL2i) and reviewed the literature. Results Three RS patients were summarized. Patient 1 was transformed into DLBCL during dose reductions in ibrutinib and achieved bone marrow (BM) minimal residual disease (MRD)-negative complete response (CR) after rituximab etoposide, dexamethasone, doxorubicin, cyclophosphamide, and vincristine (R-EDOCH) combined with BTKi treatment and sustained progression-free survival (PFS) for more than 2 years. Patient 2, who transformed at the time of diagnosis, progressed after being treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), followed by PD1 antibody combined with cytosine, arabinoside, cisplatin and dexamethasone (DHAP) treatment and PD1 antibody combined with ifosfamide, carboplatin, and etoposide (ICE) treatment. Patient 2 achieved CR after treatment with rituximab, gemcitabine, and oxaliplatin (R-GemOx) combined with BTKi. Patient 3, who transformed at the time of diagnosis with CARD11, TP53, and ATM mutations, progressed after being treated with R-EDOCH combined with BTKi and achieved MRD-negative CR after treatment with R-GemOx and venetoclax, which has continued for 3 months. We summarized new protocols utilizing targeted therapy, such as BTKi acalabrutinib, and checkpoint inhibition, and the potential role of precision medicine in future trials of RS treatment. The efficacy of these protocols as single agents or in combination with immunochemotherapy is currently being evaluated. Conclusion In our study, immunochemotherapy combined with BTKi or BCL2i achieved favorable efficacy in the treatment of RS. The treatments should be optimized by the combination of both chemotherapies and targeted therapy to develop a specific individual approach for each patient, according to previous treatment and biological characteristics.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135993193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-16DOI: 10.1007/s44178-023-00058-5
Rainer J. Klement, Jerome Figueroa, Michael Weigel, Colin E. Champ, Sami Ok, Reinhart A. Sweeney
Abstract Purpose Obesity and insulin resistance appear to worsen prognosis of breast cancer patients. We conducted a feasibility study to test a 5:2 fasting regime in breast cancer patients undergoing radiotherapy. The intervention was rated as beneficial if it would be able to reduce fat mass while significantly improving insulin sensitivity. Methods A total of 13 non-metastatic breast cancer patients were recruited and instructed to completely abstain from food on two non-consecutive days (minimum 24 h) per week during radiotherapy. Body composition was measured weekly by bioimpedance analysis. Blood parameters were assessed before and at the end of radiotherapy. The product of triglycerides and glucose was used as a proxy for insulin sensitivity. A control group on an unspecified standard diet was assigned by propensity score matching. Results A total of twelve patients completed the study. Three patients reported side effects during fasting which were mild (grade 1). Two patients reported feeling bad while fasting, whereas five had a generally good or very good feeling. The fasting group experienced an average decrease of approximately 200 g body mass ( p < 0.0001), 200 g ( p = 0.002) fat mass and 100 g muscle mass ( p = 0.047) per week, resulting in absolute reductions of 2.45 ± 1.19 kg body mass, 1.5 ± 1.6 kg fat mass and 0.7 ± 0.4 kg muscle mass. There was no improvement in insulin sensitivity and other markers of metabolic health except for gamma-glutamyltransferase which decreased by -7 ± 8 U/l. There was also no indication that 5:2 fasting protected against acute skin toxicity. Conclusions 5:2 fasting is safe and feasible for breast cancer patients during radiotherapy and suitable to significantly reduce fat mass, but beneficial metabolic effects could not be confirmed. To improve these results, future studies could combine 5:2 fasting with carbohydrate restriction, increased protein intake and/or exercise. Trial registration Registered on ClinicalTrials.gov under NCT05861362 on May 12, 2023 (retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT05861362 ).
{"title":"Feasibility and metabolic effects of a 5:2 fasting intervention in women with breast cancer during radiotherapy","authors":"Rainer J. Klement, Jerome Figueroa, Michael Weigel, Colin E. Champ, Sami Ok, Reinhart A. Sweeney","doi":"10.1007/s44178-023-00058-5","DOIUrl":"https://doi.org/10.1007/s44178-023-00058-5","url":null,"abstract":"Abstract Purpose Obesity and insulin resistance appear to worsen prognosis of breast cancer patients. We conducted a feasibility study to test a 5:2 fasting regime in breast cancer patients undergoing radiotherapy. The intervention was rated as beneficial if it would be able to reduce fat mass while significantly improving insulin sensitivity. Methods A total of 13 non-metastatic breast cancer patients were recruited and instructed to completely abstain from food on two non-consecutive days (minimum 24 h) per week during radiotherapy. Body composition was measured weekly by bioimpedance analysis. Blood parameters were assessed before and at the end of radiotherapy. The product of triglycerides and glucose was used as a proxy for insulin sensitivity. A control group on an unspecified standard diet was assigned by propensity score matching. Results A total of twelve patients completed the study. Three patients reported side effects during fasting which were mild (grade 1). Two patients reported feeling bad while fasting, whereas five had a generally good or very good feeling. The fasting group experienced an average decrease of approximately 200 g body mass ( p < 0.0001), 200 g ( p = 0.002) fat mass and 100 g muscle mass ( p = 0.047) per week, resulting in absolute reductions of 2.45 ± 1.19 kg body mass, 1.5 ± 1.6 kg fat mass and 0.7 ± 0.4 kg muscle mass. There was no improvement in insulin sensitivity and other markers of metabolic health except for gamma-glutamyltransferase which decreased by -7 ± 8 U/l. There was also no indication that 5:2 fasting protected against acute skin toxicity. Conclusions 5:2 fasting is safe and feasible for breast cancer patients during radiotherapy and suitable to significantly reduce fat mass, but beneficial metabolic effects could not be confirmed. To improve these results, future studies could combine 5:2 fasting with carbohydrate restriction, increased protein intake and/or exercise. Trial registration Registered on ClinicalTrials.gov under NCT05861362 on May 12, 2023 (retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT05861362 ).","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"137 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136113834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：